Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer

Breast J. 2022 Mar 7:2022:5169405. doi: 10.1155/2022/5169405. eCollection 2022.

Abstract

Discoidin domain receptor 2 (DDR2) is arising as a promising therapeutic target in breast carcinoma (BC). The ability of DDR2 to bind to collagen promotes protumoral responses in cancer cells that influence the tumor microenvironment (TME). Nonetheless, the interrelation between DDR2 expression and TME modulation during BC progression remains poorly known. For this reason, we aim to evaluate the correlation between intratumoral expression of DDR2 and the infiltration of the main TME cell populations, cancer-associated fibroblasts (CAFs), and tumor-associated macrophages (TAMs). First, collagen and DDR2 expression levels were analyzed in human invasive BC samples. Then, DDR2 status correlation with tumor aggressiveness and patient survival were retrieved from different databases. Subsequently, the main pathways, cell types, and tissues correlated with DDR2 expression in BC were obtained through bioinformatics approach. Finally, we studied the association of DDR2 expression with the recruitment of CAFs and TAMs. Our findings showed that, together with the expected overexpression of TME markers, DDR2 was upregulated in tumor samples. Besides, we uncovered that altered TME markers were linked to DDR2 expression in invasive BC patients. Consequently, DDR2 modulates the stromal reaction through CAFs and TAMs infiltration and could be used as a potential worse prognostic factor in the treatment response of invasive BC.

MeSH terms

  • Breast Neoplasms* / pathology
  • Cancer-Associated Fibroblasts*
  • Collagen / metabolism
  • Discoidin Domain Receptor 2* / genetics
  • Discoidin Domain Receptor 2* / metabolism
  • Female
  • Humans
  • Prognosis
  • Tumor Microenvironment
  • Tumor-Associated Macrophages*

Substances

  • Collagen
  • DDR2 protein, human
  • Discoidin Domain Receptor 2